<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>retinal lipid metabolism &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/retinal-lipid-metabolism/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 03 Dec 2025 00:14:30 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>retinal lipid metabolism &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Anti-Ceramide Immunotherapy Treats Diabetic Retinopathy</title>
		<link>https://bioengineer.org/anti-ceramide-immunotherapy-treats-diabetic-retinopathy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 03 Dec 2025 00:14:26 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[apoptosis reversal in retinopathy]]></category>
		<category><![CDATA[ceramide-targeted immunotherapy]]></category>
		<category><![CDATA[diabetic retinopathy therapy]]></category>
		<category><![CDATA[retinal lipid metabolism]]></category>
		<category><![CDATA[vascular permeability treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/anti-ceramide-immunotherapy-treats-diabetic-retinopathy/</guid>

					<description><![CDATA[In a pioneering breakthrough that promises a paradigm shift in the treatment of diabetic retinopathy, researchers have unveiled a novel immunotherapy strategy targeting ceramide imbalance—a fundamental biochemical disruption implicated in the progression of this debilitating eye disease. The study, recently published in Cell Death Discovery, elucidates how the modulation of ceramide levels via targeted anti-ceramide [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">304600</post-id>	</item>
	</channel>
</rss>
